Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions

• Váldodahkkit: Stefan Willmann (Dahkki), Katrin Coboeken (Dahkki), Yang Zhang (Dahkki), Hannah Mayer (Dahkki), Ibrahim Ince (Dahkki), Emir Mesic (Dahkki), Kirstin Thelen (Dahkki), Dagmar Kubitza (Dahkki), Anthonie W. A. Lensing (Dahkki), Haitao Yang (Dahkki), Peijuan Zhu (Dahkki), Wolfgang Mück (Dahkki), Henk‐Jan Drenth (Dahkki), Jörg Lippert (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2021-10-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Rivaroxaban has been investigated in the EINSTEIN‐Jr program for the treatment of acute venous thromboembolism (VTE) in children aged 0 to 18 years and in the UNIVERSE program for thromboprophylaxis in children aged 2 to 8 years with congenital heart disease after Fontan‐procedure. Physiolo...